The addition of small amounts of the patient's plasma to normal plasma (containing clotting factor
activities of about 100 IU/dL, thereby balancing potential clotting factor
deficiencies) produced severe and nonlinear aPTT prolongation (see Fig.
7) These clotting factors
and fibrinogen are critical for normal hemostasis.
In a series of eight consecutive hemophiliac patients with chronic hepatitis C virus (HCV) infection treated at one center with a combination of ribavirin and interferon alfa-2b, five patients had moderate or severe hemophilia that required significantly less use of clotting factors
on average during each month of treatment than in the 6 months prior to combination therapy (1,605 U/mo vs.
An adult with severe hemophilia typically will experience eight to 10 bleeds per month and self-administer 1,500 to 4,000 units of clotting factor
Patients with factor IX levels that are 5% or more of normal typically require infusion of clotting factor
only after an accident or for surgery.
The bleeding can only be stopped by injecting clotting factor
, whether extracted from other people's blood or artificially created.
But there was such a small amount of clotting factor
in a pint of plasma, that hemophiliacs would need vast amounts of plasma to increase their clotting factor
Other measures of rFIXFc's activity in the body reinforce its long-lasting characteristics: the mean time for maintaining a normal clotting factor
activity level (time to 1 percent) was 11 days for rFIXFc compared to 5 days for BeneFIX and the average rate at which rFIXFc was cleared from the body was 3.
Contract award: the concentrate of clotting factor
vii - zzp-115/15.
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB(publ) (Sobi) (STO: SOBI) have committed to produce one billion international units (IUs) of clotting factor
therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress.
Prof Bikha Ram said that the primary treatment for moderate to severe haemophilia is a factor replacement therapy, which involves replacing the blood's deficient clotting factor
This interaction - between a clotting factor
and a cell membrane - has baffled scientists for decades.
Therefore," he said, "people with hemophilia need injections of the missing clotting factor
to stop bleeding.
Haemophilia causes excessive bleeding because there is a lack of clotting factor
in the blood.
Six patients with severe hemophilia A who underwent gene therapy in a phase I clinical trial tolerated the procedure well, although the treatment failed to cure the condition by producing sustained and sufficient levels of the missing clotting factor